EU Patent Court Invalidates Enanta Patent in Pfizer Paxlovid Dispute

• The EU's Unified Patent Court ruled Enanta Pharmaceuticals' patent invalid on October 29, 2026.
• The court found its infringement suit against Pfizer over Paxlovid in 18 participating EU member states unfounded because of that ruling.
• Pfizer had sought revocation of the patent; a hearing on both claims took place on September 29, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-437774), on October 29, 2026, and is solely responsible for the information contained therein.